Congratulations Professor Marie Scully

Immune TTP is a life-threatening disease, and the current treatment options do not  halt fully the extensive clot formation in small blood vessels throughout the body, leaving patients at risk for significant morbidity and early death.   Cablivi is a novel therapy, based on nanobody technology, preventing platelet binding to von willebrand factor. The results from the HERCULES phase III trial demonstrate that Cablivi has the potential to address a major unmet medical need and to help those facing the potentially devastating consequences of this disorder.” Marie Scully, M.D, professor of hematology at University College London Hospitals, and lead author of the HERCULES study

Read the full paper